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The gastrointestinal microbiome plays an important role in limiting susceptibility to infection with Clostridioides difﬁcile. To better understand the ecology
of bacteria important for C. difﬁcile colonization resistance, we developed an experimental platform to simplify complex communities of fecal bacteria through dilution
and rapidly screen for their ability to resist C. difﬁcile colonization after challenge, as
measured by ⬎100-fold reduction in levels of C. difﬁcile in challenged communities.
We screened 76 simpliﬁed communities diluted from cultures of six fecal donors and
identiﬁed 24 simpliﬁed communities that inhibited C. difﬁcile colonization in vitro.
Sequencing revealed that simpliﬁed communities were composed of 19 to 67 operational taxonomic units (OTUs) and could be partitioned into four distinct community
types. One simpliﬁed community could be further simpliﬁed from 56 to 28 OTUs
through dilution and retain the ability to inhibit C. difﬁcile. We tested the efﬁcacy of
seven simpliﬁed communities in a humanized microbiota mouse model. We found
that four communities were able to signiﬁcantly reduce the severity of the initial C.
difﬁcile infection and limit susceptibility to disease relapse. Analysis of fecal microbiomes from treated mice demonstrated that simpliﬁed communities accelerated recovery of indigenous bacteria and led to stable engraftment of 19 to 22 OTUs from
simpliﬁed communities. Overall, the insights gained through the identiﬁcation and
characterization of these simpliﬁed communities increase our understanding of the
microbial dynamics of C. difﬁcile infection and recovery.
ABSTRACT

IMPORTANCE Clostridioides difﬁcile is the leading cause of antibiotic-associated diar-

rhea and a signiﬁcant health care burden. Fecal microbiota transplantation is highly effective at treating recurrent C. difﬁcile disease; however, uncertainties about the undeﬁned composition of fecal material and potential long-term unintended health
consequences remain. These concerns have motivated studies to identify new communities of microbes with a simpler composition that will be effective at treating disease.
This work describes a platform for rapidly identifying and screening new simpliﬁed communities for efﬁcacy in treating C. difﬁcile infection. Four new simpliﬁed communities of
microbes with potential for development of new therapies to treat C. difﬁcile disease are
identiﬁed. While this platform was developed and validated to model infection with C.
difﬁcile, the underlying principles described in the paper could be easily modiﬁed to develop therapeutics to treat other gastrointestinal diseases.
KEYWORDS Clostridioides difﬁcile, FMT, colonization resistance, microbiome,

simpliﬁed communities

C

lostridioides difﬁcile is the most common cause of antibiotic-associated diarrhea
(1–3). Estimates of annual health care costs associated with treating C. difﬁcile
infection (CDI) in the United States range from $1 billion to $4.8 billion (4). Although
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uncomplicated infections are typically self-limiting, severe infections require treatment
(5). For approximately 25% of patients, resolution of primary infection is followed by
one or more rounds of recurrent C. difﬁcile infection (rCDI) (6), which diminishes the
quality of life and contributes to overall health care costs (7, 8).
To cause disease, ingested C. difﬁcile spores must germinate into vegetative cells
that produce toxins. The bile salt cholate and its derivatives stimulate C. difﬁcile
germination, along with cogerminants glycine and other amino acids (9, 10). The
gastrointestinal microbiome plays key roles in limiting symptomatic CDI by competing
with C. difﬁcile for nutrients (11–13), producing metabolites that inhibit C. difﬁcile
growth (14–18), maintaining immune homeostasis (19–21), and metabolizing primary
bile salts into secondary bile salts that inhibit the growth of vegetative cells (9, 22, 23).
Antibiotic treatment leads to loss of GI microbiome diversity (24–26), is a key risk factor
for primary infection (27–30), and contributes to susceptibility to recurrent disease.
Several different therapies are currently used to treat rCDI and act to limit different
aspects of cell growth and pathogenicity. Clinical cure rates of 70% have been reported
following extended-pulsed administration of the antibiotic ﬁdaxomicin (31). An 80%
cure rate has been reported for patients with primary and recurrent CDI treated with
bezlotoxumab, an antibody that targets C. difﬁcile toxin B (32). Fecal microbiome
transplantation (FMT) for treatment of rCDI has reported cure rates from 44 to 100%
(33, 34). However, concern for potential adverse events (for examples, see reference 35)
motivates ongoing studies to develop alternatives to FMT to treat rCDI.
Deﬁned community microbial therapeutics are one alternative to FMT under investigation. Previous studies have demonstrated success in administration of a consortium
of 10 (36) or 33 (37) human fecal bacteria for treatment of rCDI. Despite these advances,
no deﬁned microbial therapeutic is currently available for treatment of CDI. One
limitation to developing microbial community therapeutics is the availability of appropriate models for rapid screening. We developed a coupled in vitro and in vivo platform
to screen simple microbial communities for their ability to prevent CDI. We identiﬁed
four simpliﬁed communities that limited C. difﬁcile growth in vitro and reduced the
severity of disease in vivo. While the potential of these communities to treat disease in
humans is unknown, the approaches could be applied to identiﬁcation of additional
simpliﬁed communities to treat rCDI and microbiome-linked diseases.
RESULTS
Identiﬁcation of simpliﬁed communities that limit C. difﬁcile growth in vitro. To
identify simpliﬁed communities that could suppress C. difﬁcile, we applied a dilution/
extinction strategy (38, 39) as outlined in Fig. 1A. In this approach, undiluted fecal
communities are simpliﬁed through dilution, with abundant organisms preserved and
rare organisms randomly distributed or lost as predicted by the Poisson distribution.
Undiluted fecal communities were established in minibioreactor arrays (MBRAs)
from six individual fecal donors (D1 to D6) and allowed to stabilize (Fig. 1A). Cell density
was measured by nonselective plating and used with published operational taxonomic
unit (OTU) abundance data (40) to estimate dilutions needed to simplify communities.
Following dilution, simpliﬁed communities were stabilized in continuous culture before
challenge with 104 vegetative C. difﬁcile cells. We measured C. difﬁcile proliferation in
each bioreactor over time and identiﬁed nine simpliﬁed communities that lowered C.
difﬁcile levels ⬎10,000 times and 15 communities that decreased C. difﬁcile levels ⬎100
times compared to C. difﬁcile cultivated alone in bioreactors (Fig. 1B).
CDI-resistant simpliﬁed communities separate into distinct community types.
To better understand how dilution impacted community composition, we compared
the 16S rRNA gene content between a subset of undiluted donor communities (D2 to
D4) and C. difﬁcile-resistant simpliﬁed communities (SC1 to SC5) (Fig. 1C). The median
number of OTUs in the undiluted communities was 67; dilution reduced the median
numbers of OTUs to 50 and 42 in the simpliﬁed communities diluted 10⫺4 and 10⫺5,
respectively (Fig. 2A).
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FIG 1 Identiﬁcation of simpliﬁed communities that inhibit C. difﬁcile proliferation through dilution/extinction community
assembly. (A) Overview of process to identify simpliﬁed communities. (B) Log10 C. difﬁcile levels measured in diluted
communities on day 5 or 6 following challenge. Closed triangles, C. difﬁcile (CD) cultured alone; open circles:, C. difﬁcile cultured
in the presence of undiluted communities (0) and communities diluted 10⫺4 (4) and 10⫺5 (5) cultured from indicated fecal
sample donors. Solid lines represent geometric means of samples. Dashed lines demarcate inhibition of C. difﬁcile levels by 102
and 104, with the number of samples per category indicated. (C) Schematic representation of samples generated over the
course of experiments as described in the text. Red typeface indicates samples that failed to provide protection from C. difﬁcile
colonization at the step indicated.

We compared differences in community structure across simpliﬁed communities
(Fig. 2C) and used Dirichlet multinomial mixtures to identify community types and
discriminatory taxa (41) (Fig. 2D). We found that the data best partitioned into four
community types, with community type A containing SC1 and SC5 communities, while
SC2, SC3, and SC4 separated into community types B to D, respectively.
Forty-ﬁve OTUs accounted for 80% of the difference between community types in
the model (Fig. 2D). Many of these OTUs were present in all samples, but they varied
in abundance by community type. Notable features of community type A included
Bacteroides, Peptostreptococcaceae, and Lachnospiraceae OTUs. Peptostreptococcaceae
number 31, which was detected in 3 of 4 type A communities, was 100% identical to
C. difﬁcile 16S rRNA, indicating potential experimental contamination of these communities prior to C. difﬁcile challenge. Type B communities had higher levels of Anaerostipes, Clostridium_sensu_stricto, Clostridium XI, and Peptoniphilus; Akkermansia, Blautia,
Clostridium XVIII, and Enterococcus were enriched in type C communities; and Acidaminococcus, Bilophila, and Fusobacterium were enriched in type D communities.
Simpliﬁed communities retain the ability to suppress C. difﬁcile when recultured. We selected 17 of the 24 C. difﬁcile-resistant SC1 to SC5 cultures for retesting
July/August 2020 Volume 5 Issue 4 e00387-20
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FIG 2 Comparison of microbial communities present in undiluted and simpliﬁed communities that inhibit C. difﬁcile
growth. (A and B) The number of OTUs (A) and microbial diversity (inverse Simpson) (B) detected in undiluted communities
(squares) and communities diluted 10⫺4 (circles) and 10⫺5 (triangles) are plotted. Lines represent medians; P values of
⬍0.05 as calculated by one-way Kruskal-Wallis testing are reported. (C) Principal-coordinate analysis (PCoA) visualization
of Bray-Curtis dissimilarities between C. difﬁcile-resistant communities SC1 to SC5. Colors represent different SCs as
indicated; dilutions are indicated by shapes. Percent variation described by each axis is indicated in parentheses. (D)
Forty-ﬁve OTUs that most signiﬁcantly contribute to partitioning of SC1 to SC5 into the indicated four community types
(A to D). The log2-transformed percent abundance of each OTU is plotted across all samples. Samples are arranged by
donor and community type as indicated at the top. Values ranged from 0.01% (yellow) to 64% (dark blue) of total
sequences as indicated; pale yellow indicates that there were no detected sequences (ND). Simpliﬁed community replicate
names are indicated in boldface, underlining indicates communities selected for reculturing as described in the text.
Table S1 contains data from all 147 OTUs that account for differences between community types.
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based on previous ability to suppress C. difﬁcile growth (9/9 that suppressed ⬎104;
8/24 that suppressed ⬎102) and variation in microbiome composition (indicated by
boldface type in Fig. 2D). Simpliﬁed communities were established from frozen
stocks in triplicate MBRAs and allowed stabilization prior to challenge with C.
difﬁcile. Thirteen of the 17 communities were able to inhibit C. difﬁcile upon
reculturing (Fig. 1C; see also Fig. S1 in the supplemental material). Five communities
suppressed C. difﬁcile growth ⬎10,000-fold across all three replicates, two suppressed C. difﬁcile ⬎100-fold across all three replicates, and six communities
suppressed C. difﬁcile in at least one replicate (Fig. S1). We selected one replicate
from each community type described in Fig. 2D that was also able to suppress C.
difﬁcile upon reculturing to test in a mouse model of disease. SC1A, SC2A, SC3A, and
SC4A replicates were selected; replicate names were simpliﬁed to SC1 to SC4 for
testing in mice.
SC1 and SC2 suppress CDAD. We tested SC1 to SC4 for the ability to suppress C.
difﬁcile-associated disease (CDAD) in a humanized microbiota mouse (HMbmouse)
model of disease (42). Two positive controls were used to test for suppression of CDAD:
FMT freshly prepared from our colony of HMbmice (M-FMT) and a cryopreserved aliquot
of human FMT previously used successfully in a CDI fecal transplant program (H-FMT;
T. Savidge, personal communication). Mice were treated with antibiotics to disrupt the
microbiome and then gavaged with cells from simpliﬁed communities SC1 to SC4,
M-FMT, or H-FMT on 3 consecutive days; control mice were treated with a vehicle
(phosphate-buffered saline [PBS]) (Fig. 3A). Body mass was measured daily beginning
with the ﬁrst day of gavage to test for potential toxicity of communities. Because mice
treated with SC4 exhibited ⬃5% body mass loss from baseline prior to C. difﬁcile
challenge (Fig. 3B), they were excluded from further analyses.
Following C. difﬁcile challenge, mice treated with PBS exhibited a decline in body
mass (Fig. 3C) and shed C. difﬁcile in their feces (Fig. 3E). In contrast, SC1-treated mice
maintained their body mass, with levels similar to those observed in the two positive
controls, M-FMT- and H-FMT-treated mice (Fig. 3C), and exhibited more rapid clearance
of C. difﬁcile in feces (Fig. 3E). Trends toward reduced body mass loss in SC2- and
SC3-treated mice (Fig. 3C) and more rapid clearance of C. difﬁcile in feces of SC2-treated
mice (Fig. 3E) were not statistically signiﬁcant.
Because C. difﬁcile was cleared more rapidly in SC1- and SC2-treated mice, we tested
whether these communities would reduce susceptibility to recurrent disease. Previously, we demonstrated that relapse could be induced through a single intraperitoneal
(i.p.) injection of clindamycin (42). Four weeks following the initial C. difﬁcile challenge,
the majority of mice no longer shed C. difﬁcile at detectable levels in their feces (Fig. 3E).
We treated mice with a single clindamycin i.p. injection and then measured changes in
body mass and C. difﬁcile levels. Consistent with relapse, we observed a modest body
mass decline (Fig. 3D) and an increase of C. difﬁcile in feces (Fig. 3E) of PBS-treated mice.
In contrast, there was a modest body mass gain, reduced shedding of C. difﬁcile in feces,
and more rapid clearance of C. difﬁcile in SC1- and SC2-treated mice following relapse.
M-FMT- and H-FMT-treated mice had a more modest body mass gain that was not
statistically signiﬁcant from the mass of PBS-treated mice.
SC2 can be further simpliﬁed and still inhibit C. difﬁcile growth. To test whether
either SC1 or SC2 could be further simpliﬁed, cultures were diluted to a concentration
of 250 CFU/ml (10⫺6 dilution); Poisson calculations indicated that this dilution should
reduce the complexities of SC1 and SC2 to 17 and 31 OTUs, respectively. Final simpliﬁed
communities (FS) were allowed to stabilize prior to challenge with C. difﬁcile. Although
10⫺6 dilutions of SC1 (designated FS1A to -E) lost the ability to inhibit C. difﬁcile, 10⫺6
dilutions of SC2 (designated FS2A to -E) continued to inhibit C. difﬁcile growth (Fig. 4A).
C. difﬁcile inhibition was lost when SC2 communities were diluted another 10-fold.
We analyzed the effects of further simpliﬁcation on community composition and
found that the number of OTUs declined from a median of 60 in SC2 cultures to
medians of 28 and 9 in communities diluted 10⫺6 and 10⫺7 (Fig. 4B). In addition,
July/August 2020 Volume 5 Issue 4 e00387-20
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FIG 3 SC1 and SC2 suppress C. difﬁcile-associated disease in the HMbmouse model. (A) Overview of
infection and recurrence protocol used to evaluate simpliﬁed communities and FMT treatments. Mice
were treated with a mixture of ﬁve antibiotics (⫹5 Abx) in the drinking water for 6 days as described
previously (42). After 2 days on fresh water, mice were treated once daily with microbial communities as
indicated in panels B to E or with a vehicle (PBS) for 3 days. One day prior to C. difﬁcile infection,
clindamycin was administered intraperitoneally (Clinda IP). On the third day of administration of
microbial communities, mice were challenged with C. difﬁcile (Cdiff). Disease severity and levels of C.
difﬁcile were monitored during initial infection and following induction of relapse with intraperitoneal
injection of clindamycin. In panels B to E, treatments are indicated as follows: PBS, dark blue (n ⫽ 9);
HMbmouse FMT (M-FMT), magenta (n ⫽ 9); human FMT (H-FMT), teal (n ⫽ 9); SC1, dark purple (n ⫽ 9); SC2,
light blue (n ⫽ 9); SC3, violet (n ⫽ 9); and SC4, black (n ⫽ 8). (B) Percentage of day ⫺2 body mass on day
0 (prior to C. difﬁcile challenge) following 2 days of treatment with simpliﬁed communities. (C) Percentage
of day 0 body mass on day 2 following initial infection (D) Percentage of relapse day 0 body mass 2 days
following relapse. (E) Levels of C. difﬁcile measured in the feces of treated mice on days indicated below
the graph. Boxes represent the interquartile ranges, horizontal lines indicate the medians, and vertical
lines indicate the ranges of data collected from replicate mouse samples at each time point. Signiﬁcance
of differences between microbe- and PBS-treated mice in each panel were evaluated with one-way
Kruskal-Wallis testing with Dunn’s correction for multiple comparisons. P values less than 0.05 are
reported. Two mice lost from PBS (days 3 and 4) and HMbmouse FMT-treated groups (day 3) were
included in calculations until death. Mice treated with SC3 were not tested for resistance to recurrent
infection. C. difﬁcile levels in H-FMT-treated mice were not tested on relapse day 10. Longitudinal data
collected during initial infection and relapse are plotted in Fig. S2.

microbial diversity decreased (Fig. 4C) and species evenness increased (Fig. 4D) with
increasing levels of dilution. The majority of OTUs lost through dilution were classiﬁed
in the order Clostridiales (Fig. 4E). We selected three ﬁnal simpliﬁed communities (FS2A,
FS2B, and FS2C) to test for the ability to inhibit CDAD in HMbmice.
FS2B and FS2C suppress CDAD in HMbmice. We used the experimental approach
outlined in Fig. 3 to test ﬁnal simpliﬁed communities FS2A, FS2B, and FS2C. As controls,
we administered M-FMT, SC2, and PBS. Similar to the ﬁndings in our initial study,
PBS-treated mice exhibited body mass loss following challenge with C. difﬁcile and
weight loss was prevented by treatment with M-FMT (Fig. 4F). Treatment with SC2
prevented body mass loss, contrasting with prior results in which SC2 treatment was
partially protective. Changes in efﬁcacy could be due to the shifts in microbial composition upon the reculturing of SC2 (Fig. 4E). FS2B- and FS2C-treated mice were also
protected from CDAD, whereas mice treated with community FS2A lost body mass at
a level similar to that of PBS-treated mice (Fig. 4F).
July/August 2020 Volume 5 Issue 4 e00387-20
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FIG 4 Identiﬁcation of ﬁnal simpliﬁed (FS) microbial communities that suppress C. difﬁcile in MBRA and HMbmouse
models of CDI. (A) Plot of log10 C. difﬁcile levels on the ﬁnal day in culture with recultured SC1 (closed blue circles)
and SC2 (closed green circles) and in recultured SC1 and SC2 that were further simpliﬁed to 10⫺6-fold (open circles)
and 10⫺7-fold (open squares). Lines represent medians. (B to D) Number of OTUs (B), microbial diversity (inverse
Simpson index) (C), and species evenness (Simpson evenness index) (D) of recultured SC2 and communities diluted
10⫺6 and 10⫺7. Lines represent medians; any signiﬁcant differences (P ⬍ 0.05) detected in distributions of
communities as determined by one-way Kruskal-Wallis testing are reported. (E) Differences in abundance of OTUs
present above 0.1% of total sequences in at least two replicate SC2, FS2A, FS2B, or FS2C cultures. Samples are
indicated to the left of the plot; data in boldface type are from the cultures shown in panel A; the ﬁrst SC2 replicate
is from the data reported in Fig. 2, and the additional SC2, FS2A, and FS2B replicates were collected from bioreactor
cultures used to gavage HMbmice in panels F to H. Yellow represents ⬍0.01% abundance and blue represents ⬎ 64% of total sequences as indicated by shading of log2-transformed relative abundance data; pale yellow
indicates that no sequences were detected (ND). In panels F to H, data were collected from HMbmice subjected to
treatment indicated as follows: PBS, dark blue (n ⫽ 18); M-FMT, magenta (n ⫽ 17); SC2, light blue (n ⫽ 17); FS2A,
violet (n ⫽ 9); FS2B, teal (n ⫽ 17); and FS2C, black (n ⫽ 8). Treatments were administered as described for Fig. 3A.
(F) Percentage of day 0 body mass on day 2 of infection. (G) Percentage of relapse day 0 body mass on day 2 of
relapse. (H) Log10 levels of C. difﬁcile in mouse feces on days indicated. Boxes represent the interquartile ranges,
horizontal lines indicate the medians, and vertical lines indicate the ranges of data collected from replicate mouse
samples at each time point. Signiﬁcant differences (P ⬍ 0.05) in distributions of community-treated mice compared
to PBS-treated mice as determined by one-way Kruskal-Wallis testing with Dunn’s correction for multiple comparisons are reported. Longitudinal data from treatments shown in panels F to H are reported in Fig. S3.
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PBS-treated mice shed C. difﬁcile in feces at similarly high levels across all time points
tested (Fig. 4H). In FS2C-treated mice, C. difﬁcile levels were signiﬁcantly lower than in
PBS-treated mice on day 1 and day 7 of infection. In SC2-treated mice, C. difﬁcile levels
were signiﬁcantly lower than in PBS-treated mice only on day 1 of infection. FS2A- and
FS2B-treated mice showed little reduction in levels of C. difﬁcile shedding. M-FMTtreated mice had signiﬁcantly lower levels of C. difﬁcile than PBS-treated mice at all time
points.
Following induction of relapse, we observed an ⬃3% median reduction in body
mass in PBS-treated mice on day 2 following i.p. injection (Fig. 4G). Mice treated with
SC2, FS2B, or FS2C showed ⬍0.5% median body mass loss, whereas FS2A-treated mice
exhibited ⬃5% median body mass loss. M-FMT-treated mice exhibited ⬃1% decrease
in body mass. We also observed more rapid clearance of C. difﬁcile in FS2B- and
FS2C-treated mice (Fig. 4H).
Treatment with simpliﬁed communities has persistent effects on the fecal
microbiome. We analyzed microbial communities from mouse fecal samples on days
1, 4 or 5, and 7 and relapse days 0, 2, and 7. Sequence data obtained from mice were
pooled with bioreactor data to facilitate tracking of bacteria present in simpliﬁed
communities in treated mice. We found that sequences that clustered at ⬎99% average
nucleotide identity (ANI) (Table S2) provided greater resolution of OTUs distinct to in
vitro-cultured simpliﬁed communities and M-FMT-treated HMbmice than sequences that
clustered at ⬎97% ANI (Table S3). With sequences clustered at ⬎99% ANI, 90% of OTUs
found in M-FMT-treated HMbmice were not detected in in vitro cultures and likely
represent indigenous bacteria. Similarly, 81% of OTUs found in in vitro cultures were not
detected in FMT-treated HMbmice. Subsequent analyses used OTUs that clustered
at ⬎99% ANI.
The number of OTUs detected on day 1 following infection were 25 to 50% lower
across all treatment groups than those observed in the FMT sample collected from mice
not treated with antibiotics (Fig. 5A, HMbmouse). Treatment with M-FMT partially
restored OTU abundance and microbial diversity on day 1; full recovery to levels
observed in untreated mice was not observed until day 4 or 5 during infection. In
PBS-treated mice, the median number of OTUs detected in fecal samples increased over
time but did not return to the levels detected in untreated mice. Treatment with SC2,
FS2C, or FS2B signiﬁcantly increased the number of OTUs detected on day 1 compared
to that in PBS-treated mice. Later increases in OTU abundance in FS2C-treated mice
paralleled ﬁndings for FMT-treated mice. For SC2- and FS2B-treated mice, OTU abundance increased over time but not to the extent observed in FMT-treated mice. Neither
OTU abundance nor microbial diversity was signiﬁcantly different between FS2Atreated and PBS-treated mice over the ﬁrst week of infection. Treatment with FMT, SC2,
FS2B, and FS2C also signiﬁcantly increased microbial diversity compared to that in
PBS-treated mice (Fig. 5B).
Similarities in community composition between the baseline HMbmouse sample not
treated with antibiotics and communities in the feces of treated mice were calculated
(Fig. 5C). In M-FMT-treated mice, fecal communities had low similarities to the baseline
HMbmouse sample on day 1, but similarities increased by day 7 (Fig. 5C). In contrast,
similarities between PBS-treated mice and the baseline untreated HMbmouse sample
were signiﬁcantly lower than M-FMT-treated mice through relapse day 0. Compared to
PBS-treated mice, FS2C- and SC2-treated mice exhibited an accelerated return toward
the baseline microbiome composition. FS2B-treated mice exhibited a return to baseline
microbiome that paralleled that in PBS-treated mice. In contrast, FS2A-treated mice
exhibited signiﬁcantly reduced recovery of microbiome composition compared to that
of PBS-treated mice, indicating that FS2A treatment may suppress recovery of the fecal
microbiome.
Treatments shift the composition of indigenous bacteria. We identiﬁed 98 OTUs
that were signiﬁcantly enriched or depleted in treatments that accelerated microbiome
recovery (FMT, FS2C, and SC2) compared to treatments with more prolonged disrupJuly/August 2020 Volume 5 Issue 4 e00387-20
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FIG 5 Treatment with SC2 and FS2C restores microbial diversity and shifts microbiome composition
toward baseline state observed in HMbmice not treated with antibiotics. 16S rRNA gene sequence data
were obtained from bacteria present in the feces of mice treated with PBS (dark blue), M-FMT (magenta),
SC2 (light blue), FS2A (violet), FS2B (teal), or FS2C (black) on days 1, 4 or 5, and 7 following initial C.
difﬁcile infection and days 0, 2, and 7 relative to initiation of relapse with clindamycin i.p. (For
FS2A-treated mice, 16S rRNA gene sequence data were obtained only from samples collected during
initial infection for FS2A-treated mice.) 16S rRNA sequence data were also obtained from a pooled fecal
sample collected from an HMbmice not treated with antibiotics that was used for FMT administration. (A
and B) Number of OTUs (A) and microbial diversity (inverse Simpson index) (B) measured in sample
collected from HMbmice not treated with antibiotics used for FMT administration (HMbmouse) and in
samples collected from treated mice at time points indicated below the graph. (C) Similarity to baseline
HMbmouse sample used for FMT administration measured in samples at time points indicated below
graph (similarity ⫽ 1 ⫺ Bray-Curtis dissimilarity). Boxes represent the interquartile ranges, horizontal lines
indicate the medians, and vertical lines indicate the ranges of data collected from replicate mouse
samples at each time point. Signiﬁcance of differences in microbe-treated compared to PBS-treated
animals at each time point were evaluated with one-way Kruskal-Wallis testing with Dunn’s correction for
multiple comparisons; P values of ⬍0.05 are reported.

tion (PBS, FS2A, and FS2B) for at least one of the time points tested (Table S3). We
focused on OTUs with the largest predicted effect sizes (linear discriminant analysis
[LDA] ⬎ 3 [Fig. 6]). Three OTUs, Erysipleotrichaceae number 4, Biﬁdobacterium number
12, and Bacteroidales number 19, were signiﬁcantly enriched in FS2C-, SC2-, and
FMT-treated mice at all time points. Erysipelotrichaceae number 8, Blautia number 31,
and Clostridium XIVa number 80 were enriched in FS2C-, SC2-, and FMT-treated mice on
day 1, whereas several Porphyromonadaceae OTUs (numbers 6, 7, 10, 75, 39, and 48) as
well as three Firmicutes OTUs (Erysipelotrichaceae number 17, Lachnospiraceae number
109, and Olsenella number 48) were enriched in FS2C-, SC2-, and FMT-treated mice at
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FIG 6 Treatment with simpliﬁed communities alters recovery of indigenous microbes. We used linear
discriminant analysis effect size (LEfSe) to identify signiﬁcantly enriched or depleted taxa between
treatments that accelerated microbiome recovery in Fig. 5C (M-FMT, FS2C, and SC2 [Restored]) and
treatments with more prolonged disruption (PBS, FS2A, and FS2B [Disrupted]). Independent analyses
were performed for samples on days 1, 4 or 5, and 7 and relapse day 0; OTUs with LDA values determined
by LEfSe of ⬎3 for at least one time point are shown. Intensity of shading correlates to the log2transformed median percent abundance measured for the treated mice at the indicated time points, with
median abundances of ⬎64% shaded dark blue and median values equal to 0.01% shaded dark yellow.
Samples in which sequences were below the detection limit (ND, not detected) are shaded pale yellow.
OTUs in bold typeface are indigenous to HMbmice as described in Table S2. OTUs in standard typeface
were found only in simpliﬁed communities. Blautia number 31 and Bacteroides number 3 were found in
both HMbmice and simpliﬁed communities. Peptostreptococcaceae number 35 is likely C. difﬁcile, as the
representative sequence has 100% identity to C. difﬁcile and abundance over the course of infection
correlates well with C. difﬁcile levels reported in Fig. 3 and 4. The complete set of OTUs identiﬁed by LEfSe
is provided in Table S4.

later time points. On day 1 of infection, Peptostreptococcaceae number 35 and Enterococcus number 28 were enriched in the feces of PBS-, FS2A-, and FS2B-treated mice,
whereas Bacteroides number 3, Bacteroides number 9, and Parabacteroides number 1
were enriched during the later stages of infection. These results demonstrate that
return toward the baseline microbiome conﬁguration correlates with restoration of
members of multiple phyla (Bacteroidetes, Firmicutes, and Actinobacteria), whereas
continued disruption correlates with increased abundance of Bacteroides OTUs and a
Peptostreptococcaceae OTU that is likely C. difﬁcile.
Bacteria from simpliﬁed communities persist in the feces of treated mice. We
tracked the fate of OTUs present in in vitro-cultured simpliﬁed communities over time
in mice treated with simpliﬁed communities. On day 1 following infection, ⬃60% of
OTUs present in in vitro-cultured simpliﬁed communities could be detected in the feces
of treated mice (Fig. 7A; median OTU levels ranged from 43 to 55 OTUs). Levels of
simpliﬁed community OTUs decreased over time, with the lowest number of OTUs (16
to 23) detected on relapse day 0 (Fig. 7A). Following induction of relapse, the number
of OTUs detected from the original in vitro-cultured simpliﬁed communities increased
to 44 to 48. These results indicate that these OTUs had likely persisted below the level
of detection and reemerged when other OTUs declined following clindamycin treatJuly/August 2020 Volume 5 Issue 4 e00387-20
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FIG 7 A subset of bacteria from simpliﬁed communities persists over time in treated mice. (A) Numbers of OTUs
in SC2 (light blue), FS2A (violet), FS2B (teal), and FS2C (black) in vitro cultures that persist over time in the feces of
treated mice. Lines represent median values at each time point, and error bars represent interquartile ranges.
Signiﬁcance of differences observed between treatment groups at each time point during the initial infection (days
1, 4 or 5, and 7) were evaluated with one-way Kruskal-Wallis testing with Dunn’s correction for multiple
comparisons; P values of ⬍0.05 are reported in panel B. (B) Data from days 4 or 5 and 7 replotted from panel A.
The box represents the interquartile range, horizontal line indicates the median, and vertical lines indicate the
range of data collected from fecal communities. (C) Log2-transformed percent abundance of OTUs that persist over
time in mice treated with SC2, FS2A, FS2B, and/or FS2C. OTUs detected in in vitro samples were designated
persistent if the median level in a treatment group on day 7 and/or relapse day 2 sample was ⬎0.01%. Intensity
of shading correlates to the median percent abundance measured for the treated mice at the indicated time points.
OTUs in boldface type have also been detected in HMbmice as described in Table S2. Abundance data from
persistent OTUs at later times during infection (relapse days 0 and 7) and from OTUs abundant in day 0 samples
that did not persist over time in treated mice are presented in Table S5.

ment. OTUs that persisted over time were phylogenetically diverse (Fig. 7C). High levels
of a Phascolarctobacterium OTU (number 22) and three Bacteroides OTUs (numbers 3,
11, and 16) were detected across all community-treated mice, indicating that these
bacteria likely engrafted well.
The trend for preservation of OTUs from simpliﬁed communities followed a different
trajectory in FS2A-treated mice. The median number of FS2A OTUs detected increased
to 65 on day 4 or 5 and returned to 46 on day 7 (Fig. 7A); values were signiﬁcantly
higher than those observed in mice treated with other simpliﬁed communities (Fig. 7B).
Consistent with this observation, several Bacteroides OTUs present in in vitro cultures of
all four simpliﬁed communities were only detected in the feces of FS2A-treated mice on
day 7. This increased persistence of OTUs from FS2A was also consistent with the
delayed return to baseline microbiome composition observed in these mice (Fig. 5C).
Bacteria originating from simpliﬁed communities reemerge during relapse. We
also investigated signiﬁcant differences in microbiome composition between treatment
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FIG 8 Treatment with SC2, FS2C and FS2B led to distinct microbiome responses during disease relapse.
LEfSe was used to identify OTUs that differed signiﬁcantly between treatment groups in the feces of mice
on days 2 and 7 following induction of relapse with clindamycin i.p. Independent analyses were
performed for samples on relapse days 2 and 7; OTUs with LDA values determined by LEfSe of ⬎3 for at
least one time point are shown. The complete set of LEfSe data is shown in Table S6. Median abundance
of OTUs in in vitro SC2, FS2C, and FS2B cultures as well as all the feces of treated mice on day 1 and
relapse day 0 samples are included for comparison as described in the text.

groups during relapse and identiﬁed 26 OTUs that showed high levels of difference
between treatment groups during relapse. Approximately 70% of these OTUs enriched
in the feces of SC2-, FS2C-, and FS2B-treated mice on relapse day 2 likely originated
from the in vitro-cultured simpliﬁed communities (Fig. 8). Approximately 20% of OTUs
enriched on relapse day 2 were enriched on day 1 of infection, indicating that the
response to relapse was not identical to the initial disruption but shared some similarities. Similar to the kinetics observed during initial infection (Fig. 6), 11 of 26 OTUs
were also signiﬁcantly enriched on relapse day 7, while the remainder had decreased
in abundance.
DISCUSSION
We described a new pipeline for identifying and rigorously testing simpliﬁed
communities with the ability to protect against C. difﬁcile infection. We identiﬁed 24
new simpliﬁed communities with the ability to inhibit C. difﬁcile in vitro. Several of the
OTUs detected in these simpliﬁed communities were classiﬁed into families (Lachnospiraceae, Ruminococcaceae, Clostridiaceae, and Bacteroidaceae) and genera (Bacteroides, Clostridium XIVa, Anaerostipes, Coprococcus, Dorea, Roseburia, and Blautia) found
depleted in the fecal microbiomes of people who are susceptible to C. difﬁcile and
restored following FMT treatment (43–47). In contrast, some OTUs were classiﬁed
into families less often linked to resistance to C. difﬁcile colonization (e.g., Veillonella,
Eggerthella, Clostridium XVIII, and Acidaminococcus) or more correlated with susceptibility to C. difﬁcile infection (Enterococcus, Streptococcus, and Escherichia/Shigella). Thus,
the approach we described leads to communities distinct from those based upon
predictive ecological modeling and may provide additional insights into C. difﬁcile
colonization resistance.
By testing simpliﬁed communities in an HMbmouse model, we determined that only
a subset of the tested communities conferred protection in vivo. Treatment with one
community, SC4, resulted in loss of body mass consistent with toxicity of one or more
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members of this community. Although it is not clear which community member(s) in
SC4 are toxic, SC4 contains a Bilophila OTU that could be the source of toxicity;
treatment of speciﬁc-pathogen-free (SPF) mice with Bilophila wadsworthia caused
weight loss as a result of systemic inﬂammation (48). Treatment with SC1, SC2, FS2B,
and FS2C signiﬁcantly reduced the initial body mass loss associated with severe disease
and decreased C. difﬁcile loads early in infection, similar to treatment with HMbmouse
FMT (M-FMT). While the magnitudes of effects varied, we observed a signiﬁcant
negative correlation between C. difﬁcile levels on day 1 of infection and body mass on
day 2 of infection (Fig. S4), with lower levels of C. difﬁcile on day 1 predictive of reduced
body mass loss on day 2 of infection. Thus, a potential mechanism for simpliﬁed
communities to limit the severity of CDI in vivo is by delaying the germination or
outgrowth of C. difﬁcile spores. Similar reductions in C. difﬁcile levels on day 1 following
infection coupled to an ⬃50% reduction in body mass loss were reported by Bufﬁe
et al. (22) when mice were treated with a consortium of four strains. In this case, early
reductions in C. difﬁcile levels were linked with restoration of secondary bile acid
production by Clostridium scindens, as well as unknown functions contributed by other
members of the simple community. Delaying germination or outgrowth could prevent
severe disease by altering the dynamics of the host immune response between
proinﬂammatory responses known to cause disease and anti-inﬂammatory responses
that provide protection from C. difﬁcile epithelial damage (21, 49, 50).
Comparison of microbiome changes in the feces of mice treated with communities
that limit (FS2C, SC2, and M-FMT), partially limit (FS2B), or fail to limit (FS2A and PBS)
CDAD may explain some of the observed differences in disease progression. Treatment
with FS2C, SC2, or M-FMT signiﬁcantly limited body mass loss and altered the levels of
C. difﬁcile shedding; these communities also exhibited a more rapid return toward the
baseline microbiome conﬁguration observed in HMbmice not treated with antibiotics.
Return toward baseline was associated with an increased abundance of members of the
indigenous microbiome, including several Porphyromonadaceae OTUs. Porphyromonadaceae were found to be depleted in the feces of humans and mice susceptible to C.
difﬁcile (51, 52). Enhanced restoration of indigenous microbes observed in FS2C- and
SC2-treated mice could be due to the restoration of syntrophic interactions between
indigenous microbes and those found in simpliﬁed communities and/or suppression of
factors (i.e., C. difﬁcile metabolism [53] and innate immune activation [54]) that promote
microbiome disruption.
Mice treated with FS2B showed limited body mass loss during initial infection but
did not show signiﬁcantly altered C. difﬁcile shedding in feces and exhibited a slower
return to baseline microbiome conditions. A return to baseline microbiome conditions
could, therefore, be important for C. difﬁcile clearance but may not be required to
mitigate initial disease severity. Treatment with FS2A, which failed to provide protection in vivo, was associated with signiﬁcantly lower levels of restoration of indigenous
microbes. Previous reports have indicated that speciﬁc probiotic formulations can delay
the return to a nondisrupted microbiome conﬁguration due to suppression of indigenous microbes (55); this could also be true for FS2A-treated mice. Further studies are
needed to evaluate these hypotheses.
A subset of OTUs that originated from simpliﬁed communities persisted over time
in the feces of treated mice. While the abundance of these OTUs diminished over time,
continued colonization was demonstrated following induction of relapse. Persistence of
these simpliﬁed community OTUs likely played a key role in limiting susceptibility to
recurrent disease. One OTU of note was Phascolarctobacterium. A recent study demonstrated that administration of Phascolarctobacterium species to cefoperazone-treated
mice reduces mortality, possibly by competing with C. difﬁcile for succinate in the
disrupted gastrointestinal (GI) tract (56). Other OTUs of note include those classiﬁed as
Blautia, Ruminococcaceae, and Eisenbergiella. Colonization with members of the Ruminococcaceae family and the Eisenbergiella and Blautia genera was correlated with a 60%
reduced risk for CDI in allogeneic hematopoieitic stem cell patients (57). Our results are
also consistent with a previous study of microbiome restoration following FMT in
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human patients that found a balance between engraftment of donor bacteria, persistence of bacteria present in the feces of infected patients, and emergence of previously
undetected bacteria (58).
Dilution-extinction provided a rapid way to screen simpliﬁed communities for the
ability to prevent C. difﬁcile infection. Development of diverse treatment consortia for
CDI is important, as C. difﬁcile is known to ﬁll different nutritional niches (59) and fecal
transplant studies indicate differential engraftment of species between patients treated
with the same fecal sample (60). However, further reﬁnement is needed before communities progress to clinical testing. Isolation of individual strains from simpliﬁed
communities prior to community reassembly and efﬁcacy testing will ensure the
identity of the treatment consortia. In spite of these limitations, the approaches
outlined in this report represent a signiﬁcant advance in the throughput of testing for
simpliﬁed communities to limit C. difﬁcile infection and could potentially be adapted to
identify simpliﬁed communities to treat other diseases linked to microbiome disruption.
MATERIALS AND METHODS
Fecal samples, bacterial strains, and cultivation conditions. Fecal samples were provided by
anonymous subjects between the ages of 25 and 64 years who self-identiﬁed as healthy and had not
consumed antibiotics for at least 2 months or probiotics for at least 2 days prior to donation. Fecal
samples were prepared as described previously (61). The previously described ribotype 027 isolate C.
difﬁcile 2015 was used for all experiments (61). All cultivation was performed at 37°C under an
atmosphere of 5% H2, 5% CO2, and 90% N2.
Identiﬁcation of simpliﬁed communities through dilution/extinction. Fecal samples were prepared and inoculated into MBRAs containing bioreactor medium 3 (BRM3) (62) as described previously
(40). Brieﬂy, frozen fecal aliquots were thawed and used to prepare 25% (wt/vol) fecal slurries in PBS
under anaerobic conditions. After being vortexed for 5 min, the slurries were brieﬂy centrifuged (5 min,
201 ⫻ g), and clariﬁed supernatants were used to inoculate the reactors. Fecal communities were
equilibrated for 16 h in batch growth before initiation of continuous ﬂow (ﬂow rate of 1.875 ml/h; 8-h
retention time). After 5 to 6 days, an aliquot was removed for determination of cell concentration
through serial dilution and plating on BRM3 agar and determination of C. difﬁcile colonization status by
PCR as described below. (Analysis was limited to D2 to D4 and D6 communities; D1 and D5 communities
were not tested.) After 8 days, a sample was removed from each reactor and diluted to a ﬁnal
concentration of ⬃3 ⫻ 104 cells/ml (10⫺4 dilution) or 3 ⫻ 103 cells/ml (10⫺5 dilution) in BRM3. One
milliliter of each dilution was used to inoculate 5 or 6 sterile bioreactors containing 15 ml of sterile
BRM3/dilution. After 3 days under continuous ﬂow, aliquots were removed from diluted communities for
sequencing and for cryopreservation with 15% glycerol or 7.5% dimethyl sulfoxide (DMSO). One day
later, communities were challenged with 104 C. difﬁcile cells as described previously (61); C. difﬁcile levels
in reactors were determined through selective plating on TCCFA agar with 20 g/ml of erythromycin and
50 g/ml of rifampin as described previously (61). For repeat cultivation, cryopreserved stocks were
thawed and 300 l was used to inoculate triplicate reactor vessels containing 15 ml of sterile BRM3.
Communities were grown in batch for 16 h and then with continuous ﬂow for 4 days prior to challenge
with C. difﬁcile as described above.
Analysis of C. difﬁcile colonization status in undiluted communities D2, D3, D4, and D6. As
described above, 1-ml samples were removed from undiluted cultures on day 5 of cultivation. Cells were
concentrated by centrifugation at ⬃20,000 ⫻ g for 1 min. The supernatant was discarded and cells were
lysed by bead-beating in sterile water as previously described (40). One microliter of cell lysate was used
as the template in PCRs to detect C. difﬁcile tcdA or bacterial 16S rRNA (broad-range 16S rRNA primers)
using previously described primers (61) added at a ﬁnal concentration of 1 M to reaction mixtures
containing Denville Taq master mix otherwise formulated according to the manufacturer’s instructions.
After 35 cycles of ampliﬁcation (94°C for 45 s, 55°C for 30 s, and 72°C for 1 min), 10-l volumes of
products were analyzed by agarose gel electrophoresis. Undiluted cultures had positive signals for the
16S rRNA gene as expected and no signal for C. difﬁcile tcdA.
Further simpliﬁcation of SC1 and SC2. One-milliliter stocks were thawed and used to inoculate an
empty reactor vessel. The ﬂow of sterile BRM3 was initiated and allowed to ﬁll the reactor at a ﬂow rate
of 1.825 ml/h. After 3 days, cell concentrations were determined as described above. Two days later,
aliquots of cells were removed and diluted in sterile BRM3 to a ﬁnal concentration of 250 cells/ml (10⫺6
dilution) or 25 cells/ml (10⫺7 dilution). One-milliliter aliquots of cells were used to inoculate 5 (10⫺6
dilution) or 6 (10⫺7 dilution) empty, sterile reactors, which were allowed to ﬁll with sterile medium as
described above. After 2 (SC2) or 3 (SC1) days of ﬂow, aliquots were removed for sequence analysis and
cryopreservation. One (SC1) or 15 (SC2) days later, simpliﬁed communities were challenged with 104
vegetatively growing C. difﬁcile cells and levels of C. difﬁcile persisting in reactors over time were
determined through selective plating.
Cultivation of simple communities for the treatment of HMbmice. Bioreactors (65 ml) were
prepared as previously described (63). Sterile, empty bioreactors were inoculated with 1 ml of thawed
stocks and allowed to ﬁll with sterile BRM3 at a ﬂow rate of 8.125 ml/h. Communities were cultured with
ﬂow for 6 to 8 days before 10-ml aliquots of culture were removed, centrifuged (800 ⫻ g for 10 min), and
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resuspended in 1-ml anaerobic PBS for delivery to mice. Cell densities of reactor communities were
determined through selective plating on BRM3 agar; mice received doses ranging from 5 ⫻ 108 to
2 ⫻ 109 cells freshly prepared from reactors on three subsequent days.
Preparation of HMbmouse FMT and human FMT material. Fecal samples were collected from 6- to
10 week-old male and female HMbmice (42), pooled, and resuspended in anaerobic PBS at 20% (wt/vol).
Samples were vortexed for 5 min and then centrifuged at 200 ⫻ g for 2 min. Each mouse was treated with
100 l of clariﬁed fecal slurry. The human FMT preparation was prepared as described previously (64).
Treatment of HMbmice with PBS, human FMT, HMbmouse FMT, or simpliﬁed communities.
Antibiotics (61) were administered in the drinking water to 6- to 10-week-old male and female mice
(Fig. 3A). Mice were treated with 100 l of PBS, HMbmouse FMT(M-FMT), human FMT (H-FMT), or cells from
simpliﬁed communities via orogastric gavage on three subsequent days. Clindamycin (10 mg/kg of body
weight) was administered via intraperitoneal injection. Mice were challenged with 5 ⫻ 104 spores of C.
difﬁcile 2015. Three mouse experiments were performed. Mice in experiment 1 were treated with PBS,
M-FMT, H-FMT, or SC1 to SC4 (n ⫽ 9 mice/treatment group except SC4 [n ⫽ 8]). Mice in experiment 2
were treated with PBS, M-FMT or SC2, FS2A, or FS2B (n ⫽ 9 mice/treatment group except PBS [n ⫽ 10]).
Mice in experiment 3 were treated with PBS, M-FMT or SC2, FS2B, or FS2C (n ⫽ 8 mice/treatment group).
In experiments 1 and 2, ⬃100 l of inoculum from the 3rd treatment was saved for sequencing. Mouse
body mass was collected daily from days 0 to 5 following C. difﬁcile challenge and then periodically
following resolution of severe disease as indicated in ﬁgures. Mice that lost greater than 20% body mass
from day 0 or showed signs of severe disease as previously described (42) were euthanized. Mouse body
mass was also collected on day ⫺2 and day ⫺1 in experiment 1. Relapse was induced 24 (experiment
3), 28 (experiment 1), or 33 (experiment 2) days following initial C. difﬁcile infection through i.p.
administration of clindamycin (10 mg/kg). C. difﬁcile levels in fecal samples were determined through
selective plating (experiment 1) or qPCR (experiments 2 and 3) as described previously (61) at the time
points indicated.
Analysis of microbial communities through 16S rRNA gene sequencing. Nucleic acids were
extracted from mouse fecal samples and inoculum samples using the DNeasy Powersoil HTP kit (Qiagen)
and from the further-simpliﬁed SC2 samples using the Powermag microbiome kit (MoBio). The V4 region
of the 16S rRNA gene was ampliﬁed from puriﬁed DNA or directly from lysed bioreactor samples in
triplicate using dual or single indexed primers F515/R806 as described previously (40, 65). Samples were
cleaned quantiﬁed and pooled in equimolar concentrations prior to sequencing using the Illumina MiSeq
v2 2 ⫻ 250 kit as described previously (40).
All sequence analysis was performed using mothur version 1.35.1. Raw sequencing reads were quality
ﬁltered, aligned to the V4 region of Silva 16S rRNA reference release 132, preclustered into sequence
groups with ⬍1% sequence divergence, ﬁltered to remove chimeras with uchime, and classiﬁed with the
Bayesian classiﬁer using rdp database version 16 (⬎80% conﬁdence threshold) as previously described,
with the modiﬁcations noted above (40, 66). Sequence data were then rareﬁed to remove those
sequences with ⬍10 reads. Pairwise distance matrices were calculated and sequences were clustered
into OTUs with ⬎97 and ⬎99% ANI. OTUs were classiﬁed by the majority consensus rdp taxonomy within
the OTU. To better determine the potential identity of Peptostreptococcaceae OTU number 31 (⬎97%
ANI) and Peptostreptococcaceae OTU number 35 (⬎99% ANI), representative sequences from these OTUs
were compared to the nr/nt database using BLAST.
Samples were randomly subsampled to 10,000 sequences before determination of alpha and beta
diversity measures. Alpha diversity measures (number of observed OTUs, inverse Simpson diversity, and
Simpson evenness) were calculated using mothur. Principal-coordinate analysis of Bray-Curtis dissimilarities between communities were calculated and ordinates were visualized using the Phyloseq package
(version 1.30.0 [67]) running in R version 3.61. Simpliﬁed communities were partitioned into four
community types with Dirichlet multinomial mixtures as implemented in mothur version 1.44.0. Identiﬁcation of OTUs signiﬁcantly enriched between treatment groups in mouse experiments was performed
using the mothur implementation of LEfSe (40, 66). mothur was also used to calculate the Bray-Curtis
dissimilarities between treated mice and the baseline HMbmouse sample (similarity ⫽ 1 ⫺ Bray-Curtis
dissimilarity).
Ethics statement. Protocols for fecal sample collection were reviewed and approved by the
Institutional Review Boards of Michigan State University and Baylor College of Medicine. Animal use was
reviewed and approved by the Institutional Animal Care and Use Committee at Baylor College of
Medicine (protocol number AN-6675).
Data visualization and statistical analysis. Unless otherwise noted, data were visualized and
statistical analysis was performed using Prism v8.
Data availability. 16S rRNA gene sequence data have been deposited in the Sequence Read Archive
with accession number PRJNA632592.
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